Cargando…

Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke

Ischemic stroke (IS) is the most prevalent form of brain disease, characterized by high morbidity, disability, and mortality. However, there is still a lack of ideal prevention and treatment measures in clinical practice. Notably, the transplantation therapy of mesenchymal stem cells (MSCs) has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Xiao-Qian, Luo, Yong-Yin, Chang, Jun, Song, Jing-Jing, Hao, Nan, Zhao, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052343/
https://www.ncbi.nlm.nih.gov/pubmed/37007453
http://dx.doi.org/10.4252/wjsc.v15.i3.52
_version_ 1785015138839953408
author Shan, Xiao-Qian
Luo, Yong-Yin
Chang, Jun
Song, Jing-Jing
Hao, Nan
Zhao, Lan
author_facet Shan, Xiao-Qian
Luo, Yong-Yin
Chang, Jun
Song, Jing-Jing
Hao, Nan
Zhao, Lan
author_sort Shan, Xiao-Qian
collection PubMed
description Ischemic stroke (IS) is the most prevalent form of brain disease, characterized by high morbidity, disability, and mortality. However, there is still a lack of ideal prevention and treatment measures in clinical practice. Notably, the transplantation therapy of mesenchymal stem cells (MSCs) has been a hot research topic in stroke. Nevertheless, there are risks associated with this cell therapy, including tumor formation, coagulation dysfunction, and vascular occlusion. Also, a growing number of studies suggest that the therapeutic effect after transplantation of MSCs is mainly attributed to MSC-derived exosomes (MSC-Exos). And this cell-free mediated therapy appears to circumvent many risks and difficulties when compared to cell therapy, and it may be the most promising new strategy for treating stroke as stem cell replacement therapy. Studies suggest that suppressing inflammation via modulation of the immune response is an additional treatment option for IS. Intriguingly, MSC-Exos mediates the inflammatory immune response following IS by modulating the central nervous system, the peripheral immune system, and immunomodulatory molecules, thereby promoting neurofunctional recovery after stroke. Thus, this paper reviews the role, potential mechanisms, and therapeutic potential of MSC-Exos in post-IS inflammation in order to identify new research targets.
format Online
Article
Text
id pubmed-10052343
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-100523432023-03-30 Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke Shan, Xiao-Qian Luo, Yong-Yin Chang, Jun Song, Jing-Jing Hao, Nan Zhao, Lan World J Stem Cells Review Ischemic stroke (IS) is the most prevalent form of brain disease, characterized by high morbidity, disability, and mortality. However, there is still a lack of ideal prevention and treatment measures in clinical practice. Notably, the transplantation therapy of mesenchymal stem cells (MSCs) has been a hot research topic in stroke. Nevertheless, there are risks associated with this cell therapy, including tumor formation, coagulation dysfunction, and vascular occlusion. Also, a growing number of studies suggest that the therapeutic effect after transplantation of MSCs is mainly attributed to MSC-derived exosomes (MSC-Exos). And this cell-free mediated therapy appears to circumvent many risks and difficulties when compared to cell therapy, and it may be the most promising new strategy for treating stroke as stem cell replacement therapy. Studies suggest that suppressing inflammation via modulation of the immune response is an additional treatment option for IS. Intriguingly, MSC-Exos mediates the inflammatory immune response following IS by modulating the central nervous system, the peripheral immune system, and immunomodulatory molecules, thereby promoting neurofunctional recovery after stroke. Thus, this paper reviews the role, potential mechanisms, and therapeutic potential of MSC-Exos in post-IS inflammation in order to identify new research targets. Baishideng Publishing Group Inc 2023-03-26 2023-03-26 /pmc/articles/PMC10052343/ /pubmed/37007453 http://dx.doi.org/10.4252/wjsc.v15.i3.52 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Shan, Xiao-Qian
Luo, Yong-Yin
Chang, Jun
Song, Jing-Jing
Hao, Nan
Zhao, Lan
Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke
title Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke
title_full Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke
title_fullStr Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke
title_full_unstemmed Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke
title_short Immunomodulation: The next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke
title_sort immunomodulation: the next target of mesenchymal stem cell-derived exosomes in the context of ischemic stroke
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052343/
https://www.ncbi.nlm.nih.gov/pubmed/37007453
http://dx.doi.org/10.4252/wjsc.v15.i3.52
work_keys_str_mv AT shanxiaoqian immunomodulationthenexttargetofmesenchymalstemcellderivedexosomesinthecontextofischemicstroke
AT luoyongyin immunomodulationthenexttargetofmesenchymalstemcellderivedexosomesinthecontextofischemicstroke
AT changjun immunomodulationthenexttargetofmesenchymalstemcellderivedexosomesinthecontextofischemicstroke
AT songjingjing immunomodulationthenexttargetofmesenchymalstemcellderivedexosomesinthecontextofischemicstroke
AT haonan immunomodulationthenexttargetofmesenchymalstemcellderivedexosomesinthecontextofischemicstroke
AT zhaolan immunomodulationthenexttargetofmesenchymalstemcellderivedexosomesinthecontextofischemicstroke